Alkylresorcinols as a New Type of Gut Microbiota Regulators Influencing Immune Therapy Efficiency in Lung Cancer Treatment

Figure 4

AR dynamics in blood serum before and after anti-PD/PD L1 therapy observed in four groups of lung cancer patients—with positive, stable, non-negative (positive + stable), and negative dynamics. (b) Dynamics of C2 (ethylresorcinol), (c) C5 (pentylresorcinol), and (d) C15 (pentadecylresorcinol) amounts in different groups of patients according to paired Wilcoxon test ().

(a)

(b)

(c)

(d)